Details of the Drug Combinations

General Information of This Drug (ID: DMYDM68)

Drug Name

BGP-15 DMYDM68

Synonyms

66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BGP-15 + Panobinostat	DCE11OA	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.